Meeting
2018 ASCO Annual Meeting
Oxaliplatin, 5FU and nab-paclitaxel as neoadjuvant regimen in patients with resectable oesogastric adenocarcinoma: A GERCOR phase 2 study (FOXAGAST).
Authors
Sarah Sophie Watson
Institut Mutualiste Montsouris, Paris, France
Sarah Sophie Watson , Christelle De La Fouchardiere , Stefano Chong Hun Kim , Romain Cohen , Jean-Baptiste Bachet , Christophe Tournigand , Jean-Marc Ferraz , Marine Lefevre , Delphine Colin , Magali Svrcek , Aurelia Meurisse , Christophe Louvet
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Noncolorectal) Cancer
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Esophageal or Gastric Cancer
Clinical Trial Registration Number
NCT02486601
Citation
J Clin Oncol 36, 2018 (suppl; abstr 4035)
DOI
10.1200/JCO.2018.36.15_suppl.4035
Abstract #
4035
Poster Bd #
224
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Randomized phase II study comparing neoadjuvant FLOT versus DOS for patients with type 4 or large type 3 gastric cancer (JCOG2204).
First Author: Izuma Nakayama
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Docetaxel-based triplet neoadjuvant therapy for esophageal adenocarcinoma: A comprehensive analysis of outcomes spanning over a decade.
First Author: James Tankel
Poster
2015 ASCO Annual Meeting
Pathological response to neoadjuvant 5-FU, oxaliplatin, and docetaxel (FLOT) versus epirubicin, cisplatin, and 5-FU (ECF) in patients with locally advanced, resectable gastric/esophagogastric junction (EGJ) cancer: Data from the phase II part of the FLOT4 phase III study of the AIO.
First Author: Claudia Pauligk
Poster
2013 ASCO Annual Meeting
Interim safety analysis of a phase III trial with 5-FU, oxaliplatin, and docetaxel (FLOT) versus epirubicin, cisplatin, and 5-FU (ECF) in patients with locally advanced, resectable gastric/oesophagogastric junction (OGJ) cancer: The AIO-sto-0210 FLOT4 study.
First Author: Claudia Pauligk